British study finds higher immune response when mixing Pfizer, AstraZeneca COVID-19 vaccines with Moderna; World Health Organization strongly advises against the use of convalescent plasma to treat COVID-19; disparities in pay by gender among physicians.
According to a study published yesterday in The Lancet, people who received a first dose of AstraZeneca or Pfizer/BioNTech COVID-19 vaccines were shown to exhibit higher antibodies and T-cell responses when given the Moderna vaccine 9 weeks later. As reported by Reuters, the immune response was shown to be higher than the threshold set by the traditional 2-dose schedule of AstraZeneca’s vaccine, which may promote flexible dosing in low- and middle-income countries where vaccine supply is scarce. No safety concerns were cited, but limitations of the study included its older adult and primarily White cohort.
As reported by CNBC, the World Health Organization (WHO) issued a strong recommendation yesterday against the use of convalescent plasma to treat COVID-19, amid research showing it provided no improvement in patients. The blood plasma, donated from an individual who recovered from the virus, was hypothesized to enhance a patient’s antibodies to fight infection, but WHO conversely found no clear benefit for critical outcomes such as mortality and mechanical ventilation. Convalescent plasma had been previously authorized on an emergency basis for all hospitalized patients in August 2020 prior to the approval of COVID-19 vaccines and other treatments, and it was thought to be a major therapeutic breakthrough at the time.
A survey published yesterday in Health Affairs showed that female physicians earn less than male physicians when first beginning their career, with an estimated $2 million gap in pay over a simulated 40-year career. According to The New York Times, the survey of more than 80,000 physicians served as the largest analysis to date on physician salaries, collected between 2014 and 2019, in which male physicians earned an average of $8.3 million over a 40-year career and women made roughly $6.3 million—a nearly 25% difference. Gender pay disparities were shown to differ across specialties, with gaps highest among surgeons ($2.5 million) and lowest for primary care physicians ($920,000).
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More